OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "GELIZOVIT";ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ГЕЛИЗОВИТ"
发明人:
KHOROVETS, Genrikh Markovich,ХОРОВЕЦ, Генрих Маркович
申请号：
RURU2014/000708
公开号：
WO2016/010451A1
申请日:
2014.09.23
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
The invention relates to the chemical and pharmaceutical industry and consists of a rectal gel substance for treating diseases of the intestinal/digestive tract, including nonspecific ulcerative colitis, Crohn's disease, fistulae, etc., and also complications during the course of treatment of said diseases. The invention provides an antimicrobial and antiprotozoal effect and has good penetration capabilities. The technical result achieved by carrying out the claimed invention consists in increasing the effectiveness of treating non-infectious inflammatory diseases of the intestinal/digestive tract, and in shortening the duration of treatment. Said technical result is achieved by means of a polycomplex gel for treating diseases of the intestinal/digestive tract, said gel containing metronidazole and thymogen as active substances, and containing the following auxiliary substances, in the following composition and ratio of components, in grams, with a total mass of gel of 150 grams: metronidazole: 0.1-2g； thymogen: 0.001-0.05g； carbopol: 0.2-1.0g； propylene glycol: 8.0-11.0g； EDTA disodium salt: 0.001-0.08g； propyl parahydroxybenzoate: 0.015-0.04g； methyl parahydroxybenzoate: 0.035-0.08g； sodium hydroxide: an amount sufficient for producing the necessary pH； distilled water: the remainder.L'invention se rapporte au domaine de l'industrie chimique et pharmaceutique et consiste en un agent sous forme de gel rectal pour le traitement d'affections de la voie gastro-intestinale, dont la colite ulcéreuse non spécifique, la maladie de Crohn, les fistules, etc., ainsi que les complications au cours de ces maladies. L'invention a une action antimicrobienne et anti-protozoaire et possède de bonnes capacités de pénétration. Le résultat technique de la présente invention consiste en une plus grande efficacité du traitement de maladies inflammatoires non infectieuses de la voie gastro-intestinale, et en une diminution de la durée du traitement. Ce résultat technique est atteint gr
